Cargando…
Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanothera...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636108/ https://www.ncbi.nlm.nih.gov/pubmed/34867360 http://dx.doi.org/10.3389/fphar.2021.750847 |
_version_ | 1784608467762282496 |
---|---|
author | Zhang, Huan Xu, Jinshun Gao, Binyang Wang, Hong Huang, Jianbo Zhou, Jie Yang, Rui Yan, Feng Peng, Yulan |
author_facet | Zhang, Huan Xu, Jinshun Gao, Binyang Wang, Hong Huang, Jianbo Zhou, Jie Yang, Rui Yan, Feng Peng, Yulan |
author_sort | Zhang, Huan |
collection | PubMed |
description | Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanotherapy and immunotherapy. To overcome this barrier, we designed a new synergistic cascade strategy (SCS) that uses mild hyperthermia and smart drug delivery system (SDDS) to alter TME resistance in order to improve drug delivery and therapeutic efficacy of TNBC. Methods: Mild hyperthermia was produced by microwave (MW) irradiation. SDDS were formulated with thermosensitive polymer-lipid nanoparticles (HA-BNPs@Ptx), composed of polymer PLGA, phospholipid DPPC, hyaluronic acid (HA, a differentiation-44-targeted molecule, also known as CD44), 1-butyl-3-methylimidazolium-L-lactate (BML, a MW sensitizer), and paclitaxel (Ptx, chemotherapy drug). 4T1 breast tumor-bearing mice were treated with two-step MW combined with HA-BNPs@Ptx. Tumors in mice were pretreated with first MW irradiation prior to nanoparticle injection to modify and promote TME and promoting nanoparticle uptake and retention. The second MW irradiation was performed on the tumor 24 h after the injection of HA-BNPs@Ptx to produce a synergistic cascade effect through activating BML, thus, enhancing a hyperthermia effect, and instantly releasing Ptx at the tumor site. Results: Multifunctional CD44-targeted nanoparticles HA-BNPs@Ptx were successfully prepared and validated in vitro. After the first MW irradiation of tumors in mice, the intratumoral perfusion increased by two times, and the nanoparticle uptake was augmented by seven times. With the second MW irradiation, remarkable antitumor effects were obtained with the inhibition rate up to 88%. In addition, immunohistochemical analysis showed that SCS therapy could not only promote tumor cell apoptosis but also significantly reduce lung metastasis. Conclusion: The SCS using mild hyperthermia combined with SDDS can significantly improve the efficacy of TNBC treatment in mice by modifying TME and hyperthermia-mediated EPR effects. |
format | Online Article Text |
id | pubmed-8636108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86361082021-12-02 Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy Zhang, Huan Xu, Jinshun Gao, Binyang Wang, Hong Huang, Jianbo Zhou, Jie Yang, Rui Yan, Feng Peng, Yulan Front Pharmacol Pharmacology Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanotherapy and immunotherapy. To overcome this barrier, we designed a new synergistic cascade strategy (SCS) that uses mild hyperthermia and smart drug delivery system (SDDS) to alter TME resistance in order to improve drug delivery and therapeutic efficacy of TNBC. Methods: Mild hyperthermia was produced by microwave (MW) irradiation. SDDS were formulated with thermosensitive polymer-lipid nanoparticles (HA-BNPs@Ptx), composed of polymer PLGA, phospholipid DPPC, hyaluronic acid (HA, a differentiation-44-targeted molecule, also known as CD44), 1-butyl-3-methylimidazolium-L-lactate (BML, a MW sensitizer), and paclitaxel (Ptx, chemotherapy drug). 4T1 breast tumor-bearing mice were treated with two-step MW combined with HA-BNPs@Ptx. Tumors in mice were pretreated with first MW irradiation prior to nanoparticle injection to modify and promote TME and promoting nanoparticle uptake and retention. The second MW irradiation was performed on the tumor 24 h after the injection of HA-BNPs@Ptx to produce a synergistic cascade effect through activating BML, thus, enhancing a hyperthermia effect, and instantly releasing Ptx at the tumor site. Results: Multifunctional CD44-targeted nanoparticles HA-BNPs@Ptx were successfully prepared and validated in vitro. After the first MW irradiation of tumors in mice, the intratumoral perfusion increased by two times, and the nanoparticle uptake was augmented by seven times. With the second MW irradiation, remarkable antitumor effects were obtained with the inhibition rate up to 88%. In addition, immunohistochemical analysis showed that SCS therapy could not only promote tumor cell apoptosis but also significantly reduce lung metastasis. Conclusion: The SCS using mild hyperthermia combined with SDDS can significantly improve the efficacy of TNBC treatment in mice by modifying TME and hyperthermia-mediated EPR effects. Frontiers Media S.A. 2021-11-15 /pmc/articles/PMC8636108/ /pubmed/34867360 http://dx.doi.org/10.3389/fphar.2021.750847 Text en Copyright © 2021 Zhang, Xu, Gao, Wang, Huang, Zhou, Yang, Yan and Peng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Huan Xu, Jinshun Gao, Binyang Wang, Hong Huang, Jianbo Zhou, Jie Yang, Rui Yan, Feng Peng, Yulan Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy |
title | Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy |
title_full | Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy |
title_fullStr | Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy |
title_full_unstemmed | Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy |
title_short | Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy |
title_sort | synergistic cascade strategy based on modifying tumor microenvironment for enhanced breast cancer therapy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636108/ https://www.ncbi.nlm.nih.gov/pubmed/34867360 http://dx.doi.org/10.3389/fphar.2021.750847 |
work_keys_str_mv | AT zhanghuan synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT xujinshun synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT gaobinyang synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT wanghong synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT huangjianbo synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT zhoujie synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT yangrui synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT yanfeng synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy AT pengyulan synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy |